Please login to the form below

Not currently logged in
Email:
Password:

Retroviruses found in chronic fatigue cases

In a recent study, almost 90 per cent of CFS patients showed signs of infection with a group of mouse leukaemia viruses

In a recent study, almost 90 per cent of patients with chronic fatigue syndrome (CFS) showed signs of infection with retroviruses, suggesting that antiviral drugs could be used to treat the disease.

In the US government study, researchers identified at least one of four different murine-related leukaemia viruses in 86.5 per cent of the 37 patients with CFS compared to 6.8 per cent of 44 patients without the disease.

The results suggest antiviral drugs including Merck's Isentress (raltegravir) and Gilead Science's Viread (tenofovir) should be tested for the condition.

The study published in the Proceedings of the National Academy of Sciences, supports findings from last year that linked CFS to a related infectious agent, called XMRV. But they are contrary to last month's report from the US Centers for Disease Control and Prevention that failed to find a viral link.

Murine-related leukaemia is a form of an infectious agent known to cause leukaemia and other cancers in mice. Whether it causes diseases in humans is not known.

CFS affects around 17 million people worldwide.

24th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...